SILO
Income statement / Annual
Last year (2023), Silo Pharma, Inc.'s total revenue was $72,102.00,
a decrease of 0.00% from the previous year.
In 2023, Silo Pharma, Inc.'s net income was -$3.70 M.
See Silo Pharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$72,102.00
|
$72,102.00
|
$71,264.00
|
$40,923.00
|
$40,569.00
|
$0.00
|
$847,407.00
|
-$669,480.00
|
-$145,185.00
|
-$107,114.00
|
Cost of Revenue |
$5,838.00 |
$5,838.00 |
$5,004.00 |
$176,126.00 |
$27,387.00 |
$17,550.00 |
$0.00 |
$0.00 |
$0.00 |
-$127,679.00 |
Gross Profit |
$66,264.00 |
$66,264.00 |
$66,260.00 |
-$135,203.00 |
$13,182.00 |
-$17,550.00 |
$847,407.00 |
-$669,480.00 |
-$145,185.00 |
$20,565.00 |
Gross Profit Ratio |
0.92 |
0.92 |
0.93 |
-3.3 |
0.32 |
0 |
1 |
1 |
1 |
-0.19 |
Research and Development
Expenses |
$845,092.00
|
$1.29 M
|
$693,910.00
|
$88,800.00
|
$63,465.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
General & Administrative
Expenses |
$3.08 M
|
$2.43 M
|
$2.27 M
|
$2.18 M
|
$864,180.00
|
$459,830.00
|
$313,371.00
|
$300,994.00
|
$167,700.00
|
$269,435.00
|
Selling & Marketing
Expenses |
$0.00
|
-$1.27 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$3.08 M
|
$2.43 M
|
$2.27 M
|
$2.18 M
|
$864,180.00
|
$459,830.00
|
$313,371.00
|
$300,994.00
|
$167,700.00
|
$269,435.00
|
Other Expenses |
$0.00 |
$2.17 M |
$1.95 M |
$3,000.00 |
$765,720.00 |
$314,607.00 |
$177,500.00 |
$142,500.00 |
$96,613.00 |
$0.00 |
Operating Expenses |
$3.92 M |
$3.71 M |
$2.96 M |
$2.27 M |
$927,645.00 |
$459,830.00 |
$490,871.00 |
$443,494.00 |
$264,313.00 |
$269,435.00 |
Cost And Expenses |
$3.93 M |
$3.72 M |
$2.96 M |
$2.45 M |
$955,032.00 |
$459,830.00 |
$427,961.00 |
$443,494.00 |
$264,313.00 |
$269,435.00 |
Interest Income |
$398,530.00 |
$72,637.00 |
$1,210.00 |
$11,543.00 |
$12,196.00 |
$4,218.00 |
$20,483.00 |
$49,836.00 |
$40,341.00 |
$20,565.00 |
Interest Expense |
$4,869.00 |
$2,199.00 |
$3,036.00 |
$269,267.00 |
$62,928.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Depreciation &
Amortization |
$229,378.00
|
$72,637.00
|
-$147,290.00
|
$179,919.00
|
$28,136.00
|
$17,550.00
|
-$701,104.00
|
$719,316.00
|
$192,326.00
|
$127,679.00
|
EBITDA |
-$3.63 M
|
-$3.91 M
|
$4.19 M
|
-$2.39 M
|
-$930,403.00
|
-$951,914.00
|
$0.00
|
$0.00
|
-$217,172.00
|
-$248,870.00
|
EBITDA Ratio |
-50.29 |
-49.58 |
-40.58 |
-58.48 |
-22.24 |
0 |
-1.38 |
-0.49 |
0.17 |
1.13 |
Operating Income Ratio
|
-53.47
|
-50.59
|
-38.51
|
-62.87
|
-22.93
|
0
|
-0.56
|
0.59
|
1.5
|
2.32
|
Total Other
Income/Expenses Net |
$224,509.00
|
-$279,732.00
|
$6.93 M
|
-$464,550.00
|
-$82,891.00
|
-$375,221.00
|
$826,924.00
|
-$719,316.00
|
-$192,326.00
|
$0.00
|
Income Before Tax |
-$3.63 M |
-$3.91 M |
$4.18 M |
-$3.04 M |
-$1.01 M |
-$969,463.00 |
$356,536.00 |
-$1.11 M |
-$409,498.00 |
-$376,549.00 |
Income Before Tax Ratio
|
-50.36
|
-54.19
|
58.68
|
-74.23
|
-24.98
|
0
|
0.42
|
1.66
|
2.82
|
3.52
|
Income Tax Expense |
$0.00 |
$1,163.00 |
$24,876.00 |
$92,348.00 |
$34,792.00 |
-$513,851.00 |
-$62,910.00 |
$696,500.00 |
$0.00 |
$0.00 |
Net Income |
-$3.70 M |
-$3.91 M |
$3.90 M |
-$3.13 M |
-$1.05 M |
-$969,463.00 |
$356,536.00 |
-$1.11 M |
-$409,498.00 |
-$376,549.00 |
Net Income Ratio |
-51.33 |
-54.21 |
54.78 |
-76.48 |
-25.83 |
0 |
0.42 |
1.66 |
2.82 |
3.52 |
EPS |
-1.2 |
-1.71 |
2.06 |
-2.37 |
-1.24 |
-0.99 |
0.5 |
-1.11 |
-0.4 |
-0.39 |
EPS Diluted |
-1.2 |
-1.71 |
2.03 |
-2.37 |
-1.24 |
-0.99 |
0.5 |
-1.11 |
-0.4 |
-0.39 |
Weighted Average Shares
Out |
$3.08 M
|
$2.28 M
|
$1.90 M
|
$1.32 M
|
$842,295.00
|
$982,028.00
|
$1.00 M
|
$1.00 M
|
$1.01 M
|
$958,297.00
|
Weighted Average Shares
Out Diluted |
$3.08 M
|
$2.28 M
|
$1.92 M
|
$1.32 M
|
$842,295.00
|
$982,028.00
|
$1.04 M
|
$1.00 M
|
$1.01 M
|
$958,297.00
|
Link |
|
|
|
|
|
|
|
|
|
|